Michael Houghton

Sir Michael Houghton is one of the most consequential virologists of his era — a British-born scientist whose relentless seven-year hunt for an invisible enemy led to the 1989 discovery of the hepatitis C virus, one of the most significant breakthroughs in the history of infectious disease. Born in 1949 into a working-class family in the United Kingdom, he won a scholarship to the University of East Anglia and went on to complete his PhD in biochemistry at King’s College London. What followed was a career defined by an extraordinary willingness to pursue scientific problems that others considered intractable — and to stay with them long enough to solve them.

Science speaker Sir Michael Houghton is best known for the discovery he achieved at Chiron Corporation in Emeryville, California, where he and colleagues Qui-Lim Choo, George Kuo, and Daniel Bradley undertook what he has described as “brute force” molecular biology — screening hundreds of millions of DNA clones over seven grueling years, trying at least 30 different approaches, before identifying a single positive match that proved to be a previously unknown RNA virus. That virus, named hepatitis C, was the hidden cause of the chronic liver disease that had been baffling clinicians since Harvey Alter’s NIH studies of the 1970s. The discovery enabled blood screening tests that within years virtually eliminated transfusion-transmitted hepatitis C worldwide, and laid the scientific foundation for antiviral treatments that today cure over 95% of infected patients. Houghton also co-discovered the hepatitis D genome in 1986 — a second landmark contribution that further transformed the understanding of viral liver disease.

From Discovery to Vaccine: A Career Still at the Frontier

In a gesture that speaks to the depth of his principles, Houghton declined the 2013 Canada Gairdner International Award — one of science’s most prestigious prizes — because his co-discoverers had not been included. He joined the University of Alberta in 2010 as Li Ka Shing Professor of Virology and Director of the Li Ka Shing Applied Virology Institute, where he has spent the subsequent years pursuing a challenge that eluded him even after the Nobel: an effective vaccine against hepatitis C. Having conducted four clinical trials in three countries, his team published the first evidence for an efficacious HCV vaccine as early as 1994. As of 2024, a clinical trial of his latest adjuvanted recombinant vaccine candidate — designed to be effective across all global strains of the virus — has been funded and initiated at the University of Alberta, representing the most advanced HCV vaccine effort in the world.

As a Nobel Prize speaker, Sir Michael Houghton brings a rare combination of scientific depth, personal humility, and genuine passion for the unfinished work still ahead. His keynotes move fluidly between the extraordinary story of HCV’s discovery — with all its frustration, persistence, and eventual triumph — and the urgent present-tense questions of pandemic preparedness, vaccine development, and what it takes to build the research infrastructure capable of responding to the next viral threat. For healthcare, pharmaceutical, and scientific audiences, he is among the most credible and compelling voices working at the frontier of virology today.